Literature DB >> 7679801

CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.

R C Allen1, R J Armitage, M E Conley, H Rosenblatt, N A Jenkins, N G Copeland, M A Bedell, S Edelhoff, C M Disteche, D K Simoneaux.   

Abstract

The ligand for CD40 (CD40L) is a membrane glycoprotein on activated T cells that induces B cell proliferation and immunoglobulin secretion. Abnormalities in the CD40L gene were associated with an X-linked immunodeficiency in humans [hyper-IgM (immunoglobulin M) syndrome]. This disease is characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. CD40L complementary DNAs from three of four patients with this syndrome contained distinct point mutations. Recombinant expression of two of the mutant CD40L complementary DNAs resulted in proteins incapable of binding to CD40 and unable to induce proliferation or IgE secretion from normal B cells. Activated T cells from the four affected patients failed to express wild-type CD40L, although their B cells responded normally to wild-type CD40L. Thus, these CD40L defects lead to a T cell abnormality that results in the failure of patient B cells to undergo immunoglobulin class switching.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679801     DOI: 10.1126/science.7679801

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  202 in total

Review 1.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Cloning, expression and biological function of the bovine CD40 homologue: role in B-lymphocyte growth and differentiation in cattle.

Authors:  A Hirano; W C Brown; D M Estes
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4.

Authors:  John M Darlow; Alex M Farrell; David I Stott
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 5.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

6.  CD40L-null NKT cells provide B cell help for specific antibody responses.

Authors:  Hemangi B Shah; Sunil K Joshi; Mark L Lang
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

7.  A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.

Authors:  Mario I Vega; Leopoldo Santos-Argumedo; Sara Huerta-Yepez; Rosendo Luría-Perez; Vianney Ortiz-Navarrete; Armado Isibasi; Cesar R González-Bonilla
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

8.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

9.  Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome.

Authors:  K Agematsu; H Nagumo; K Shinozaki; S Hokibara; K Yasui; K Terada; N Kawamura; T Toba; S Nonoyama; H D Ochs; A Komiyama
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.